IXCHIQ Chikungunya vaccine: updated use restrictions
The MHRA has completed a safety review of IXCHIQ (chikungunya vaccine) and, following recommendations from the Commission on Human Medicines (CHM), important changes to its licensed indications have been made.
Key points
- IXCHIQ is no longer indicated for adults over 60 years of age
- The vaccine is now contraindicated in this age group
- These restrictions follow a formal safety review and CHM recommendation
- Healthcare providers and clinicians should review their vaccination protocols accordingly
Affected medication
- IXCHIQ (chikungunya vaccine)
What you should do
If you are involved in chikungunya vaccination programmes or advise patients on travel health:
- Check the updated product information and contraindications
- Do not offer IXCHIQ to patients aged 60 years and over
- Consider alternative preventive measures for older travellers to chikungunya-endemic regions
- Update your local protocols and patient information materials
For the full regulatory statement and detailed safety information, visit the MHRA drug safety update.